Catalog No.
DHJ65301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
Delta-like protein 4, Drosophila Delta homolog 4, Delta4, DLL4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NR61
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
OMP-21M18, CAS: 1243262-17-0
Clone ID
Demcizumab
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial, PMID: 32037195
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC, PMID: 29188408
A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors, PMID: 25324140
NOTCH signalling in ovarian cancer angiogenesis, PMID: 33490217
Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia, PMID: 33408769
Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer, PMID: 25388163
Brief overview of selected approaches in targeting pancreatic adenocarcinoma, PMID: 24673265
Urinary EPCR and dermcidin as potential novel biomarkers for severe adult OSA patients, PMID: 31677485
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma, PMID: 26855149
For research use only. Not for human or drug use.
